Recent studies have demonstrated that targeted blockade of both CD47 and PD‐L1 on tumour cells with a bispecific anti‐PD‐L1‐CD47 (SIRPα) showed significantly enhanced tumour targeting and therapeutic efficacy versus monotherapy (Chen, Dominik, et al., 2021; Liu, Guo, et al., 2018; Liu, Liu, et al., 2018). The gene discussed is SIRPA; the disease is neoplasm.